{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:19:07Z","timestamp":1777702747556,"version":"3.51.4"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1097\/iae.0000000000000300","type":"journal-article","created":{"date-parts":[[2014,8,8]],"date-time":"2014-08-08T10:29:11Z","timestamp":1407493751000},"page":"272-279","source":"Crossref","is-referenced-by-count":28,"title":["COMPARISON OF INTRAVITREAL TRIAMCINOLONE ACETONIDE VERSUS INTRAVITREAL BEVACIZUMAB AS THE PRIMARY TREATMENT OF CLINICALLY SIGNIFICANT MACULAR EDEMA"],"prefix":"10.1097","volume":"35","author":[{"given":"Qingyun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honghua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alp","family":"Atik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongli","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shibo","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-14-20210130","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.2337\/dc10-1580","article-title":"Targeting the pathophysiology of diabetic macular edema.","volume":"33","author":"Romero-Aroca","year":"2010","journal-title":"Diabetes Care"},{"key":"R2-14-20210130","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ophtha.2008.09.037","article-title":". Association of vitreous inflammatory factors with diabetic macular edema.","volume":"116","author":"Funatsu","year":"2009","journal-title":"Ophthalmology"},{"key":"R3-14-20210130","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3109\/02713683.2010.510257","article-title":". Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy.","volume":"35","author":"Oh","year":"2010","journal-title":"Curr Eye Res"},{"key":"R4-14-20210130","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/bjo.2007.129122","article-title":". Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).","volume":"92","author":"Paccola","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R5-14-20210130","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ajo.2007.12.031","article-title":". Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.","volume":"145","author":"Shimura","year":"2008","journal-title":"Am Journal Ophthalmol"},{"key":"R6-14-20210130","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1097\/IAE.0b013e3181853d2a","article-title":"Repeated intravitreal injection of bevacizumab for clinically significant diabetic macular edema.","volume":"28","author":"Roh","year":"2008","journal-title":"Retina"},{"key":"R7-14-20210130","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1111\/j.1755-3768.2008.01443.x","article-title":"Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide.","volume":"88","author":"Rensch","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"R8-14-20210130","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000330045","article-title":". Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema.","volume":"226","author":"Kim","year":"2011","journal-title":"Ophthalmologica"},{"key":"R9-14-20210130","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000313820","article-title":"Features of optical coherence tomography are predictive of visual outcomes after intravitreal bevacizumab injection for diabetic macular edema.","volume":"224","author":"Roh","year":"2010","journal-title":"Ophthalmologica"},{"key":"R10-14-20210130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/jop.2011.0070","article-title":"Optical coherence tomographic patterns in diabetic macula edema can predict the effects of intravitreal bevacizumab injection as primary treatment.","volume":"28","author":"Wu","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"key":"R11-14-20210130","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0002-9394(99)00033-1","article-title":"Patterns of diabetic macular edema with optical coherence tomography.","volume":"127","author":"Otani","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"R12-14-20210130","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.ophtha.2004.11.045","article-title":". Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema.","volume":"112","author":"Funatsu","year":"2005","journal-title":"Ophthalmology"},{"key":"R13-14-20210130","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/jop.2007.0128","article-title":"Intravitreal bevacizumab treatment for refractory diabetic macular edema.","volume":"24","author":"Ornek","year":"2008","journal-title":"J Ocul Pharmacol Ther"},{"key":"R14-14-20210130","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/IAE.0b013e31815ec261","article-title":". Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.","volume":"27","author":"Soheilian","year":"2007","journal-title":"Retina"},{"key":"R15-14-20210130","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","article-title":"Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans.","volume":"146","author":"Krohne","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R16-14-20210130","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.icu.0000120711.35941.76","article-title":"Corticosteroids in posterior segment disease: an update on new delivery systems and new indications.","volume":"15","author":"Ciulla","year":"2004","journal-title":"Curr Opin Ophthalmol"},{"key":"R17-14-20210130","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.survophthal.2007.12.005","article-title":"Intravitreal steroids for macular edema: the past, the present, and the future.","volume":"53","author":"Cunningham","year":"2008","journal-title":"Surv Ophthalmol"},{"key":"R18-14-20210130","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0161-6420(02)00975-2","article-title":". Intravitreal triamcinolone for refractory diabetic macular edema.","volume":"109","author":"Martidis","year":"2002","journal-title":"Ophthalmology"},{"key":"R19-14-20210130","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ajo.2011.03.033","article-title":". Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema.","volume":"152","author":"Sohn","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"R20-14-20210130","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1097\/IAE.0b013e3181e095c0","article-title":". Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab.","volume":"30","author":"Funk","year":"2010","journal-title":"Retina"},{"key":"R21-14-20210130","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ophtha.2008.09.036","article-title":". Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema.","volume":"116","author":"Roh","year":"2009","journal-title":"Ophthalmology"},{"key":"R22-14-20210130","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10792-008-9242-2","article-title":"Short-term efficacy of intravitreal bevacizumab for the treatment of macular edema due to diabetic retinopathy and retinal vein occlusion.","volume":"29","author":"Astam","year":"2009","journal-title":"Int Ophthalmol"},{"key":"R23-14-20210130","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nm1534","article-title":". Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation.","volume":"13","author":"Gao","year":"2007","journal-title":"Nat Med"},{"key":"R24-14-20210130","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/0002-9394(81)90638-3","article-title":"Macular edema and cystoid macular edema.","volume":"92","author":"Fine","year":"1981","journal-title":"Am J Ophthalmol"},{"key":"R25-14-20210130","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0039-6257(84)90233-9","article-title":"Pathology of human cystoid macular edema.","volume":"28","author":"Yanoff","year":"1984","journal-title":"Surv Ophthalmol"},{"key":"R26-14-20210130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ajo.2006.04.023","article-title":"Optical coherence tomographic patterns of diabetic macular edema.","volume":"142","author":"Kim","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R27-14-20210130","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s004170000238","article-title":"Morphological and functional analyses of diabetic macular edema by optical coherence tomography and multifocal electroretinograms.","volume":"239","author":"Yamamoto","year":"2001","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R28-14-20210130","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1167\/iovs.03-1110","article-title":". Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema.","volume":"45","author":"Audren","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R29-14-20210130","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s10384-007-0513-7","article-title":". Efficacy and retention times of intravitreal triamcinolone acetonide for macular edema.","volume":"52","author":"Kogure","year":"2008","journal-title":"Jpn J Ophthalmol"},{"key":"R30-14-20210130","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/eye.2008.10","article-title":"Short-term complications of intravitreal injections of triamcinolone and bevacizumab.","volume":"22","author":"Jonas","year":"2008","journal-title":"Eye (Lond)"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000000300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:05:04Z","timestamp":1620954304000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201502000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000000300","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}